Trial Profile
A prospective study investigating safety, tolerability and efficacy of crizotinib in Chinese subjects with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Feb 2016 New trial record